Involvement of Plasmatic Factors in the Peripheral Muscle Dysfunction of COPD Patients - In Vitro Study

Chronic Obstructive Pulmonary Clinical Trial

Official title:

Involvement of Plasmatic Factors in the Peripheral Muscle Dysfunction of COPD Patients - In Vitro Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03197909
• Other study ID #: RECHMPL17_0210
• Status: Completed
• Start date: July 6, 2017
• Est. completion date: January 31, 2019

Study information

• Verified date: September 2018
• Source: University Hospital, Montpellier
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Chronic Obstructive Pulmonary Patients is a defined by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases. It is associated with an atrophy of the skeletal muscle that impairs the patient's prognosis. The biological mechanisms of this muscle atrophy have not been elucidated, and the "spill-over theory" has recently emerged. Indeed, in COPD patients, the pulmonary inflammation is associated with a systemic low-grade inflammation, and the increased pro-inflamatory molelcules in the blood - which constitute the cellular micro-environement of the muscle fibre - could activate the mechanisms of the cell atrophy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Est. completion date: January 31, 2019
• Est. primary completion date: December 31, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 35 Years to 85 Years

Eligibility

Inclusion Criteria:

35 to 85 years old

• COPD patients: association of symtoms (breathlessness, cough, sputum) and chronic exposure to inhalated risk factors (like tobacco smoke) and a FEV1/VC ratio <70% assessed by a spirometry

• Healthy subjects: A sedentariness assessed by a Voorrips score <9.4 and/or a report of <150 min/week of moderate-to-vigorous physical activity

Exclusion Criteria:

• A recent COPD exacerbation (< 4weeks)

• The decompensation of a comorbidity

• An antioxidant supplementation or medication

• A long-term systemic corticosteroid medication

Related Conditions & MeSH terms

• Chronic Obstructive Pulmonary

Intervention

Other:
• Determination of pro-inflammatory plasma factors
Determination of pro-inflammatory plasma factors at COPD patients aged from 35 to 85 years old and Healthy subjects aged from 35 to 85 years old

Locations

Country	Name	City	State
France	Uhmontpellier	Montpellier

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Montpellier

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Level of pro-Inflamatory markers	Level of pro-Inflamatory markers in the serum	6 days
Primary	Myotube diameter of in vitro cultured myotubes	Myotube diameter of in vitro cultured myotubes from healthy subjects, exposed to the serum of healthy controls and COPD patients	6 days
Secondary	Expression and translation of markers of	Expression and translation of markers of anabolic and catabolic pathways	6 days